Martin Gosling

Martin Gosling is the Chief Scientific Officer and Co-founder of Enterprise Therapeutics, a biotech company focused on developing treatments for respiratory diseases, particularly cystic fibrosis, since February 2015. Additionally, Martin serves as an Honorary Professor of Drug Discovery and a Professor of Molecular Pharmacology at the University of Sussex, where research emphasizes drug discovery for respiratory, neurological, and oncology indications. Previously, Martin held significant roles at Novartis, including Executive Director for Integrated Biology and the Asthma, Ion Channel & Cystic Fibrosis Unit, where contributions included target identification and candidate selection for respiratory diseases. Martin's academic career began as a Lecturer in Vascular Physiology at Imperial College London, emphasizing ion channel roles in cellular signaling. Martin earned a PhD in Pharmacology from Aston University and a BSc (Hons) in Pharmacology from the University of Leeds.